US › Healthcare

Kiniksa Pharmaceuticals Ltd (KNSA)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$75.99+3.51%
Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Revenue
$243.6M
Revenue YoY
+55.4%
Net profit
$25.4M
Profit YoY
+42.6%
EPS
$0.30
EPS estimate
$0.30
Net margin
10.4%

EPS came in at 0.30 against a street estimate of 0.30 — a beat of 0.0%.

Key statistics

Market cap
$5.73B
P/E
74.2
Forward P/E
69.4
P/B
8.87
Book value
$8.39
EPS (TTM)
$0.99
52-week high
$82.94
52-week low
$31.78
50-day MA
$58.80
200-day MA
$47.98
Beta
0.09

Analyst view

Analysts rate Kiniksa Pharmaceuticals Ltd a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $78.75.

Shareholding

Insiders
3.58%
Institutions
102.79%

Largest institutional holders

FundStake
FMR Inc8.87%
Rubric Capital Management LP4.87%
Vanguard Group Inc4.05%
Baker Bros Advisors LP3.67%
TANG CAPITAL MANAGEMENT LLC2.94%
Vanguard Portfolio Management, LLC2.30%
Acadian Asset Management LLC1.74%
Vanguard Capital Management, LLC1.73%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Kiniksa Pharmaceuticals Ltd — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.